Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris

Model scores of the 29,894 trials active now.

Model score 23% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 9% of the time (336 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2018-01-11. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: subjectcellsubjects withremissionantibody
  Phrases that lowered it: and safetysafety ofthe efficacyefficacy andevidence or
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 12.8% (raises risk) · Sponsor's track record
• Sponsor's past trials: 548 (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Phase: 3 (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 305 (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Design: parallel (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Blinding: double (raises risk) · Design
• Drug's FAERS reports with a death: 14.4% (lowers risk) · Drug's FDA history
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Disease area, neurology: No (lowers risk) · Disease area
• Number of arms: 2 (raises risk) · Design
• Disease area, dermatology: Yes (raises risk) · Disease area
• Drug's FAERS reports before start: 666 (raises risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 266 (raises risk) · Drug's FDA history
• Keywords listed: 13 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris NCT02704429 · started 2016 · scored riskier than 39% of active trials completed
• A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV) NCT02383589 · started 2015 · scored riskier than 28% of active trials completed
• Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris NCT02613910 · started 2015 · scored riskier than 62% of active trials terminated
• A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus NCT03334058 · started 2017 · scored riskier than 53% of active trials completed
• A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid NCT03286582 · started 2017 · scored riskier than 15% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.